Impact of treatment on IL-4, IL-6, IL-10 and sCD25 levels in patients with Hodgkin’s Lymphoma

S222 in other PTCL with different CD30 expression levels. The aim of the study was to investigate the efficacy of BV in patients with relapsed or refractory PTCL. Methods: From March 2011 to January 2014, 74 patients were treated with BV in France in a compassionate patient program for recurrent PTCL. The diagnosis of PTCL was actually confirmed according to the 2008 WHO classification, after local histopathologic review, for 66 patients, including 56 patients with extensive immunohistochemical studies and centralized CD30 immunostaining. The primary end point was best response under BV. Progression free survival (PFS), OS, and safety, were analysed as secondary endpoints. Results: Patients were treated for: systemic ALCL (n1⁄425): ALCL ALK(n1⁄415) and ALCL ALK+ (n1⁄410); systemic PTCL (n1⁄422): PTCL NOS (n1⁄412), adult T-cell leukemia/lymphoma (n1⁄44), enteropathyassociated T-cell lymphoma (n1⁄44), and angioimmunoblastic T-cell lymphoma (n1⁄42); and cutaneous primary lymphoma (n1⁄419), Mycosis Fungoides/Sezary syndrome (n1⁄411) and Cutaneous CD30+ T-cell lymphoproliferative disorders (n1⁄48). CD30 was scored >75%, 10-70% and undetectable ( 75%) have a significant longer PFS (14.1 versus 5.7 months). Median OS was 25.9 months [95% CI 11.9; NR]. Conclusion: In this limited series of patients with different PTCL subtypes treated with BV, the level of expression of CD30 seems to impact outcome with a significantly poorer PFS for cases with a lower level of expression of CD30.